South Korea · Delayed Price · Currency is KRW Chabiotech Statistics
Total Valuation
Chabiotech has a market cap or net worth of KRW 1.58 trillion. The enterprise value is 2.69 trillion.
| Market Cap | 1.58T |
| Enterprise Value | 2.69T |
Important Dates
The next estimated earnings date is Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Chabiotech has 91.96 million shares outstanding. The number of shares has increased by 111.35% in one year.
| Current Share Class | 91.96M |
| Shares Outstanding | 91.96M |
| Shares Change (YoY) | +111.35% |
| Shares Change (QoQ) | -25.31% |
| Owned by Insiders (%) | 11.33% |
| Owned by Institutions (%) | 16.92% |
| Float | 72.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.25 |
| PB Ratio | 1.89 |
| P/TBV Ratio | 17.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -24.44 |
| EV / Sales | 2.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -12.26 |
Financial Position
The company has a current ratio of 0.67, with a Debt / Equity ratio of 1.08.
| Current Ratio | 0.67 |
| Quick Ratio | 0.59 |
| Debt / Equity | 1.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.13 |
| Interest Coverage | -1.04 |
Financial Efficiency
Return on equity (ROE) is -18.63% and return on invested capital (ROIC) is -4.26%.
| Return on Equity (ROE) | -18.63% |
| Return on Assets (ROA) | -1.51% |
| Return on Invested Capital (ROIC) | -4.26% |
| Return on Capital Employed (ROCE) | -4.55% |
| Weighted Average Cost of Capital (WACC) | 7.21% |
| Revenue Per Employee | 4.56B |
| Profits Per Employee | -395.24M |
| Employee Count | 278 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 18.30 |
Taxes
In the past 12 months, Chabiotech has paid 3.45 billion in taxes.
| Income Tax | 3.45B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +54.95% in the last 52 weeks. The beta is 0.79, so Chabiotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | +54.95% |
| 50-Day Moving Average | 19,645.60 |
| 200-Day Moving Average | 14,109.60 |
| Relative Strength Index (RSI) | 41.70 |
| Average Volume (20 Days) | 498,651 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Chabiotech had revenue of KRW 1.27 trillion and -109.88 billion in losses. Loss per share was -1,637.00.
| Revenue | 1.27T |
| Gross Profit | 354.20B |
| Operating Income | -57.15B |
| Pretax Income | -143.26B |
| Net Income | -109.88B |
| EBITDA | -853.71M |
| EBIT | -57.15B |
| Loss Per Share | -1,637.00 |
Balance Sheet
The company has 339.23 billion in cash and 905.43 billion in debt, with a net cash position of -566.21 billion or -6,157.41 per share.
| Cash & Cash Equivalents | 339.23B |
| Total Debt | 905.43B |
| Net Cash | -566.21B |
| Net Cash Per Share | -6,157.41 |
| Equity (Book Value) | 839.66B |
| Book Value Per Share | 3,986.69 |
| Working Capital | -421.85B |
Cash Flow
In the last 12 months, operating cash flow was -72.10 billion and capital expenditures -146.99 billion, giving a free cash flow of -219.09 billion.
| Operating Cash Flow | -72.10B |
| Capital Expenditures | -146.99B |
| Depreciation & Amortization | 56.29B |
| Net Borrowing | 43.02B |
| Free Cash Flow | -219.09B |
| FCF Per Share | -2,382.55 |
Margins
Gross margin is 27.93%, with operating and profit margins of -4.51% and -8.66%.
| Gross Margin | 27.93% |
| Operating Margin | -4.51% |
| Pretax Margin | -11.30% |
| Profit Margin | -8.66% |
| EBITDA Margin | -0.07% |
| EBIT Margin | -4.51% |
| FCF Margin | n/a |
Dividends & Yields
Chabiotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -111.35% |
| Shareholder Yield | -111.35% |
| Earnings Yield | -6.93% |
| FCF Yield | -13.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 2, 2014. It was a reverse split with a ratio of 0.7262.
| Last Split Date | Jun 2, 2014 |
| Split Type | Reverse |
| Split Ratio | 0.7262 |
Scores
Chabiotech has an Altman Z-Score of 0.59 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.59 |
| Piotroski F-Score | 4 |